Olaparib (Lynparza) may be beneficial for some people with advanced pancreatic cancer who have inherited mutations in the BRCA1 or BRCA2 genes, according to results from the POLO trial.
In two large clinical trials, the drugs enzalutamide (Xtandi) and apalutamide (Erleada), respectively, combined with androgen deprivation therapy, improved the survival of men with metastatic prostate cancer that still responds to hormone-suppressing therapies.
The Food and Drug Administration has approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The new approval is based on results from a phase 3 clinical trial.
The drug lenalidomide (Revlimid) may delay the progression of smoldering myeloma to multiple myeloma, according to preliminary results from an NCI-supported clinical trial.
FDA has expanded the approved use of the drug ado-trastuzumab emtansine (Kadcyla), also called T-DM1, to include adjuvant treatment in some women with early-stage HER2-positive breast cancer based on findings from a large clinical trial.
Clinical Trials Information for Patients and Caregivers
Although the experimental treatment given in clinical trials is often free, participants are usually required to pay usual care costs. This page discusses what clinical trial costs health insurance plans are required to cover, what conditions must be met for insurance to cover these cost, and what costs plans may not cover.
Some federal programs may help pay the costs of care in clinical trials for eligible beneficiaries. This page describes those programs and who they can help.
Find NCI-Supported Clinical Trials Use our search form to find a clinical trial or other research study that may be right for you or a loved one.
NCI-Supported Clinical Trials That Are Recruiting Patients
This phase 2 trial is testing several different drugs and biomarkers in patients with late-stage, ALK-positive non-small cell lung cancer whose tumors are resistant to previous ALK inhibitor therapy. Doctors will assess the overall response rates in patients in the trial’s nine treatment groups.
This phase 2 trial will test a new method for blood-forming stem cell transplantation from healthy donors to patients with a rare type of lymphoma. Patients with relapsed or resistant peripheral T-cell lymphoma will undergo either reduced-intensity conditioning therapy or immunosuppression only prior to transplantation with donated blood or bone marrow stem cells.
This phase 1 trial is testing the drug birinapant combined with intensity-modulated radiation therapy (IMRT) for patients with head-and-neck squamous cell carcinoma that has recurred after treatment with chemoradiotherapy. Researchers want to assess the side effects and determine the best dose of birinapant when combined with IMRT for future clinical trials.
